METHODS: We recruited 248 renal transplant recipients (mean age 36.48±10.54; male
(83.47%), all on Tac; MMF and prednisone in the study. Of the 248 patients; 110 had CGN; …

Methods We recruited 248 renal transplant recipients (mean age 36.48±10.54; male
(83.47%), all on Tac; MMF and prednisone in the study. Of the 248 patients; 110 had CGN; …

Introduction Tacrolimus (TAC) is the mainstay immunosuppressant for renal transplantation.
A narrow therapeutic index, multiple drug interactions, and interindividual variability in …

Calcineurin inhibitors (CNI) are metabolized by cytochrome-P4503A (CYP3A) enzymes and
extruded into the intestinal lumen by the drug efflux pump, P-glycoprotein (P-gp). The impact …

Kidney transplantation stands as the ultimate recourse for restoring vital organ functions,
particularly in cases of end-stage kidney disease where alternative treatments, such as …

Objective The immunosuppressive drug tacrolimus requires strict therapeutic monitoring due
to its narrow therapeutic index and great inter-individual variability. Cytochrome P450 3A4 …

Abstract Background Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in
the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is …

Objective: Tacrolimus is an immunosuppressive drug with a narrow therapeutic range and
wide interindividual variation in its pharmacokinetics. Cytochrome P450 (CYP) 3A and P …

Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

BACKGROUND: Genetic polymorphisms of metabolism enzymes or intestinal drug
transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal …